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Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas
aeruginosa, twenty-six ofwhich werecarbenicillin-(CARB) resistant, were tested for susceptibil-
ity to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination
with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 1o6
CFU/ml. The Klebsiella were highly resistant to TOB, MEZ, and PIP (MICg: 8,> 256, > 128
,sg/ml, respectively). Synergy was demonstrated in 53 percent (PIP/TOB) and 51 percent
(MEZ/TOB). An indifferent response was observed in 47 percent (PIP/TOB) and 49 percent
MEZ/TOB ofthe Klebsiella. PIP, MEZ, and AZL in combination with TOB showed synergism
against CARB-resistant Pseudomonas in less than 10 percent ofthestrains tested. Synergycould
be demonstrated against CARB-susceptible Pseudomonas with the combinations PIP/TOB,
AZL/TOB, and MEZ/TOB in 12 percent, 12 percent, and 24 percent, respectively, of the
twenty-five strains tested. Indifferent effects were observed in 84 percent, 88 percent, and 76
percent, respectively, ofthese same CARB-susceptible strains. These data suggest that there is no
significant difference in the incidence of synergy with these new penicillins and tobramycin
against either Pseudomonas or Klebsiella.
INTRODUCTION
Aminoglycosides, combined with semisynthetic penicillins, are the most widely
studied antibiotic combinations for use against gram-negative bacilli, the major cause
of serious sepsis in immunocompromised patients. Klebsiella and Pseudomonas
represent two of the most significant pathogens in this patient population. The use of
two or more antimicrobial agents for empiric therapy of such infections has become
common in clinical practice [15] and is based on thehope, suggested by in vitrostudies,
that the drugs may interact synergistically to inhibit infecting pathogens. There are
data from both animal and human trials that indicate improved clinical efficacy of
synergistic antibiotic combinations [1,2,14].
New broad-spectrum penicillin derivatives have been synthesized which have potent
activity against both Klebsiella and Pseudomonas. Indications for use of these agents
are unclear. Piperacillin and azlocillin have enhanced activity against Pseudomonas,
while piperacillin and mezlocillin have enhanced activity against Klebsiella compared
to carbenicillin and ticarcillin. A critical parameter in the therapy of infections with
Pseudomonas is the presence ofsynergy. This report compares the in vitro activity of
11
Address reprint requests to James T. Downs, VA Medical Center, Infectious Disease Section, Bldg. 7,
West Spring Street, West Haven, CT 06516
Copyright © 1986 by the Yale Journal of Biology and Medicine, Inc.
All rights ofreproduction in any form reserved.DOWNS ET AL.
three recently introduced semisynthetic penicillins (azlocillin, mezlocillin, and pipera-
cillin) alone and in combination with the aminoglycoside, tobramycin, against clinical
isolates ofKlebsiella species and ofPseudomonas aeruginosa to see ofthere is a clear
advantage with respect to synergy for any ofthe penicillins. Several investigators have
reported that azlocillin shows reduced efficacy against active f3-lactamase producing
strains such as Klebsiella [4,5]. Therefore, azlocillin was not tested against Klebsiella
sp. in this study.
MATERIALS AND METHODS
Bacterial Strains
Fifty-three Klebsiella species and 51 Pseudomonas aeruginosa strains were
collected as unique isolates from the microbiology laboratories of Yale-New Haven
Hospital, New Haven, CT, the Veterans Administration Medical Center, West Haven,
CT, and the Hospital of St. Raphael, New Haven, CT. Initially, the minimum in-
hibitory concentration (MIC) ofcarbenicillin for each Pseudomonas strain was tested
in duplicate with the microtiter method outlined below. Strains having MICs less than
128Ag/ml (25/51) were taken ascarbenicillin-susceptible; thosewith MICs above this
level (26/51) were defined as carbenicillin-resistant.
Antibiotics
Antimicrobial agents were generously provided as standard powders or solutions by
their manufacturers: tobramycin by Eli Lilly, Co., Indianapolis, IN; azlocillin and
mezlocillin by Miles Pharmaceuticals, West Haven, CT; piperacillin by Lederle
Laboratories, Pearl River, NY; carbenicillin by Roerig, New York, NY.
Susceptibility Testing
A single lot of Mueller-Hinton broth was used in all experiments (Difco, No.
707919). Solid medium was prepared by adding agar to a concentration of 15 percent
to MHB. This lot of MHB contained 0.1 mg/ml of calcium and 0.02 mg/ml of
magnesium. Thus both solid and liquid medium contained the same concentration of
calcium and magnesium. The media were not supplemented with additional divalent
cations. Standard Kirby Bauer disc susceptibility tests were performed using Pseudo-
monas aeruginosa, strain ATCC No. 27853, with azlocillin (75 jig), mezlocillin (75
,ug), piperacillin (100 ,g), and tobramycin (10 ug) impregnated discs. The diameters
of zones of inhibition for all discs fell within normal ranges, confirming the quality of
the solid medium.
MICs, minimum bactericidal concentrations (MBCs), and synergy were deter-
mined in microtiter plates with 96 U-shaped wells (Dynatech, Alexandria, VA)
containing the antibiotics diluted in Mueller-Hinton broth (MHB). For the MICs, 100
,ul of twofold serial dilutions of each antibiotic were added to each well. One well in
each row contained only MHB to serve as an inoculation/growth control. Bacteria
were grown overnight, then diluted in fresh broth to adensity ofapproximately 1 x 108
CFU/ml, as determined with a spectrophotometer. A semiautomatic inoculator
(Dynatech, Alexandria, VA) was used to deliver 1 x 105 CFU (1 x 106 CFU/ml) to
each well (final concentration: 1 x 106 CFU/ml). The MIC was taken as the lowest
concentration ofdrug with no visible growth after 18 hours ofincubation at 370C.
MBC data were obtained by inoculating Mueller-Hinton agar plates with an aliquot
(1.5 ul) from each well ofthe MIC plate followed by incubation at 370C for 48 hours.
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No growth was required to define the MBC (>99.9 percent killing). Thus in the
absence of killing, an aliquot would contain at least 1.5 x 103 CFUs. At 99.9 percent
killing this aliquot would contain 1.5 CFUs which would be detectable by agar
plating.
Antibiotic synergy testing employed the same microtiter broth method described
above except that dilutions of tobramycin were placed horizontally in the trays, while
those of each penicillin were placed vertically, resulting in a checkerboard array of
drug combinations. The concentrations chosen for each drug insured that a range from
one-eighth to two times the MIC for all but very resistant strains was included. The
same inoculum was delivered to each well, one well per row serving as drug-free
control. After incubation at 370C for 24 hours, the lowest concentration of drugs
showing no visible growth was taken as the best combination.
Synergy Criteria
Synergy data were evaluated using published methods [8,13] by which the
fractional inhibitory concentrations (FICs) and FIC indexes (FIXs) were calculated.
The FIC for a single antibiotic was determined as the ratio ofthe MIC ofthat drug in
combination, divided by the MIC when used alone. Thus, two FICs werecalculated for
each effective combination. The FIX was calculated as the numerical sum of the two
FICs for a given combination. The following criteria were used: FIX less than or equal
to 0.5, synergy; FIX greater than 0.5 but less than or equal to 2.0, indifferent effects;
FIX greater than 2.0, antagonism. Typical equations for these calculations are
shown:
MICX in combination
x MICX alone
FIX = FICX + FICy
RESULTS
Figure 1 shows the cumulative distribution of the MICs of bacteria tested against
the semisynthetic penicillins. In each case, carbenicillin-susceptible Pseudomonas
were slightly more susceptible than the carbenicillin-resistant strains. Azlocillin and
piperacillin appeared more active against Pseudomonas than mezlocillin, and pipera-
cillin demonstrated more activity against the carbenicillin-resistant Pseudomonas
than either ofthe other two drugs. The activities ofmezlocillin and piperacillin against
Klebsiella appeared to be similar.
The MICs and MBCs which were effective against 50 percent and 90 percent ofthe
Klebsiella and Pseudomonas strains tested are shown in Table 1. As can be seen, some
strains of Klebsiella were highly resistant to both mezlocillin and piperacillin, the
MIC90s exceeding the highest drug concentrations used. The MIC90 data for azlocillin,
mezlocillin, and piperacillin against the two groups of Pseudomonas show that these
drugs have similar anti-pseudomonal activities within groups: a twofold range for
carbenicillin-resistant Pseudomonas (64-128 ,ug/ml); a fourfold range for carbenicil-
lin-susceptible Pseudomonas (8-32 ,u/ml). Pseudomonas strains resistant to carbeni-
cillin show higher MICs for the three semisynthetic penicillins than those of the
carbenicillin-susceptible strains.
Table 2 contains a summary of data from synergy testing. The mezlocillin-
tobramycin combination synergistically inhibited 51 percent and had an indifferent
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FIG. 1.The cumulative distribution of MICs for all
ofthe strains tested are shown. The upper curves show
the activity ofazlocillin against carbenicillin-suscepti-
ble (-A-) and carbenicillin-resistant (-0-) Pseudo-
monas aeruginosa. The middle and lower curves show
the same data for mezlocillin and piperacillin, respec-
tively. In addition, the cumulative distribution of
MICs of these latter two drugs against Klebsiella
(-O-) is shown.
effect on 49 percent of the Klebsiella strains. With these same strains, piperacillin-
tobramycin showed synergism against 53 percent and indifferent effects against 47
percent. The three penicillins each in combination with tobramycin showed relatively
little synergism against either group ofPseudomonas strains. Mezlocillin-tobramycin
showed the highest degree of synergy (24 percent) against carbenicillin-susceptible
Pseudomonas. Indifferent effects for each penicillin-tobramycin combination were
seen in 100 percent (mezlocillin-tobramycin), 80 percent (azlocillin-tobramycin), and
96 percent (piperacillin-tobramycin) of the carbenicillin-resistant strains, and 76
percent, 84 percent, and 84 percent, respectively, against the carbenicillin-susceptible
TABLE 1
MICs/MBCs of Antibiotics Alone vs. Strains Tested
MIC (mcg/ml) MBC (mcg/ml)
Range 50% 90% Range 50% 90%
Klebsiella (53) MEZ 2->256 16 >256 2->256 32 >256
PIP 1->128 32 128 1->128 64 >128
TOB 0.6->8 0.5 >8 0.6->8 0.5 >8
Pseudomonas (26) AZL 2->512 16 64 4->512 32 >512
(CARB-resistant) MEZ 16->256 32 128 16->256 64 >256
PIP 4-64 8 64 4->128 16 64
TOB 0.06->8 0.12 4 0.06->8 0.25 >8
Pseudomonas (25) AZL 2-16 8 16 4-64 8 16
(CARB-susceptible) MEZ 4-64 16 32 16-128 16 64
PIP 2-16 4 8 4-16 4 16
TOB 0.06-8 0.12 1 0.06-8 0.25 1
MEZ, mezlocillin; PIP, piperacillin; AZL, azlocillin; CARB, carbenicillin; TOB, tobramycin
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TABLE 2
Effects of Antibiotics in Combination vs. Strains Tested
Antibiotic interaction
(% ofstrains)
Synergy Indifferent Antagonistic
Klebsiella (53) MEZ-TOB 51 49 0
PIP-TOB 53 47 0
Pseudomonas (26) AZL-TOB 8 80 12
(CARB-resistant) MEZ-TOB 0 100 0
PIP-TOB 4 96 0
Pseudomonas (25) AZL-TOB 12 84 0
(CARB-susceptible) MEZ-TOB 24 76 0
PIP-TOB 12 84 4
MEZ, mezlocillin; PIP, piperacillin; AZL, azlocillin; CARB, carbenicillin; TOB, tobramycin
organisms. Antagonism was observed in three strains ofcarbenicillin-resistant Pseudo-
monas tested with azlocillin-tobramycin, and in one strain ofcarbenicillin-susceptible
Pseudomonas using piperacillin-tobramycin.
DISCUSSION
Heineman and Lofton [9] tested the in vitro response ofPseudomonas to penicillin-
aminoglycoside combinations and concluded that an organism's MIC for an individual
drug gave no hint of its response to drug combinations, and that no particular
combination of drugs could be used as a screen for other combinations. With this
unpredictability assumed, this investigation was designed to determine the in vitro
efficacy oftobramycin combined with each ofthree new semisynthetic penicillins. This
study was designed to use a high inoculation density (1 x 106 CFU/ml) [5], to include
carbenicillin-resistant organisms, and to adhere to strict synergy criteria in an attempt
to evaluate these drugs under "most difficult" conditions of in vitro testing.
The analytical scheme used to assess synergy employs ratios and sums of ratios of
drug concentrations. Investigators using this method have cited synergism with FIXs
ranging from 0.3 to 0.75 [10,13]. Using the less strict criteria (FIX less than or equal to
0.75), the incidence of synergism in this study would be considerably increased.
However, the criteria used in this report (FIX less than or equal to 0.5) allowed direct
comparison of data to previous reports by authors defining synergy as a fourfold
reduction ofthe MICs of both drugs in a combination [1,3,1 11. In fact, when our data
were calculated using a fourfold reduction of the MIC for both drugs as the synergy
criteria, the results were identical.
Azlocillin, mezlocillin, and piperacillin when combined with tobramycin were shown
in this study to have similar synergistic activities. Other investigators report higher
levels of synergism (range: 32-100 percent) for penicillin-aminoglycoside pairs
[3,10,12], particularly piperacillin-gentamicin [3,6]. Although differences in tech-
nique (e.g., test method, inoculum density, analysis criteria) may account for variabili-
ty, penicillinase activity (or lack of it) is also important in the response of any
individual strain. Other investigators have used f-lactamase producing and non-
producing organisms when studying penicillin-derived drugs and have reported
multi-modal distributions of MICs with penicillin-derived drugs [5,12], suggesting
sub-populations of destructive enzyme producers. The trimodal distribution of Kleb-
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siella MICs (Fig. 1) may reflect the presence of fl-lactamase production in some
strains analyzed in this study. Also it has recently been shown [7] that selected
semisynthetic penicillins when incubated with Enterobacteriaceae species are often
inactivated after seven hours, presumably due to 3-lactamase activity. The clinical
significance ofthis inactivation is not clear.
Thesedata do not demonstrate an advantage in the amount ofsynergy achieved with
any of the combinations tested. Since it has been shown that the presence of antibiotic
synergy represents an important parameter in predicting a positive response in
Pseudomonas infections, these data may suggest there will be no clear advantage of
any one ofthese combinations over another.
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